Rankings
▼
Calendar
▼
NGEN Q4 2017 Earnings Report — NervGen Pharma Corp. Common stock Revenue & Financial Results | Market Cap Arena
NervGen Pharma Corp. Common stock
NGEN
Q4 2017 Earnings
Reported December 30, 2017
Quarter Comparison
Revenue
Operating Income
EPS (Diluted)
Metric
Q4 2017
Q3 2017
Q4 2016
QoQ Change
YoY Change
Revenue
$0
—
—
—
—
Op. Income
-$5.1K
—
—
—
—
EPS (Diluted)
$0.00
—
—
—
—
marketcaparena.com
Income Statement
Item
Amount
REVENUE
$0
Cost of Revenue
$0
GROSS PROFIT
$0
R&D Expenses
$0
Selling & Marketing
$0
General & Administrative
$0
SG&A Expenses
$5.1K
Other Expenses
$0
Operating Expenses
$5.1K
Cost & Expenses
$5.1K
OPERATING INCOME
-$5.1K
Interest Income
$0
Interest Expense
$0
Other Income/Expenses
$0
INCOME BEFORE TAX
-$5.1K
Income Tax Expense
$0
Net Income from Continuing Ops
-$5.1K
Net Income from Discontinued Ops
$0
Other Adjustments
$0
NET INCOME
-$5.1K
Net Income Deductions
$0
BOTTOM LINE NET INCOME
-$5.1K
D&A
$0
EBIT
-$5.1K
EBITDA
-$5.1K
EPS
$0
EPS Diluted
$0
marketcaparena.com
← FY 2017
NGEN Overview
Q1 2018 →